相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk
Hedi Schelleman et al.
AMERICAN JOURNAL OF MEDICINE (2010)
A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age
A-K Hamberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement- A systematic review and meta analysis
Limei Yang et al.
THROMBOSIS RESEARCH (2010)
The largest prospective warfarin-treated cohort supports genetic forecasting
Mia Wadelius et al.
BLOOD (2009)
Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
Jonatan D. Lindh et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Simvastatin: Two decades in a circle
Genovefa D. Kolovou et al.
CARDIOVASCULAR THERAPEUTICS (2008)
Differential genotype dependent inhibition of CYP2C9 in humans
Vikas Kumar et al.
DRUG METABOLISM AND DISPOSITION (2008)
Incidence and predictors of severe bleeding during warfarin treatment
Jonatan D. Lindh et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2008)
Pharmacogenetics of warfarin: current status and future challenges
M. Wadelius et al.
PHARMACOGENOMICS JOURNAL (2007)
CYP2C9 inhibition: Impact of probe selection and pharmacogenetics on in vitro inhibition profiles
Vikas Kumar et al.
DRUG METABOLISM AND DISPOSITION (2006)
Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport
T Sakaeda et al.
PHARMACEUTICAL RESEARCH (2006)
The impact of simvastatin on warfarin disposition and dose requirements
E. A. Sconce et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease
S Perreault et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6
T Prueksaritanont et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
MG Scordo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Warfarin dose adjustments based on CYP2C9 genetic polymorphisms
MW Linder et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2002)
Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele
J Shimamoto et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
